Roisín M. Connolly

5.9k total citations
105 papers, 3.0k citations indexed

About

Roisín M. Connolly is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Roisín M. Connolly has authored 105 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 30 papers in Molecular Biology and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Roisín M. Connolly's work include Cancer Treatment and Pharmacology (20 papers), Advanced Breast Cancer Therapies (16 papers) and Breast Cancer Treatment Studies (16 papers). Roisín M. Connolly is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Advanced Breast Cancer Therapies (16 papers) and Breast Cancer Treatment Studies (16 papers). Roisín M. Connolly collaborates with scholars based in United States, Ireland and United Kingdom. Roisín M. Connolly's co-authors include Kathleen Bennett, Thomas I. Barron, Vered Stearns, Kala Visvanathan, Linda Sharp, Antonio C. Wolff, Saraswati Sukumar, Nguyen K. Nguyen, Maria Cristina Figueroa Magalhães and Danijela Jelovac and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Roisín M. Connolly

99 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roisín M. Connolly United States 25 1.2k 1.2k 610 480 417 105 3.0k
Rebecca L. Stone United States 38 1.6k 1.3× 1.5k 1.3× 745 1.2× 499 1.0× 343 0.8× 136 4.6k
Juan Lin United States 26 812 0.7× 870 0.7× 360 0.6× 526 1.1× 598 1.4× 138 3.0k
Michelle A.T. Hildebrandt United States 34 655 0.5× 1.7k 1.4× 903 1.5× 473 1.0× 459 1.1× 117 3.3k
James Campbell United Kingdom 29 1.2k 1.0× 2.1k 1.7× 374 0.6× 313 0.7× 276 0.7× 61 3.3k
Giovanni Luca Gravina Italy 44 1.3k 1.0× 2.2k 1.9× 783 1.3× 1.2k 2.4× 671 1.6× 187 5.2k
Romano Demicheli Italy 33 2.1k 1.7× 710 0.6× 1.3k 2.1× 546 1.1× 411 1.0× 97 3.4k
Nicola J. Mabjeesh Israel 30 500 0.4× 1.4k 1.2× 1.1k 1.8× 845 1.8× 258 0.6× 76 3.2k
Antonio Silvani Italy 28 931 0.8× 944 0.8× 398 0.7× 765 1.6× 154 0.4× 182 3.3k
Kurt Possinger Germany 35 2.2k 1.8× 1.5k 1.3× 579 0.9× 788 1.6× 122 0.3× 101 4.4k
Alessandra Fabi Italy 36 2.4k 2.0× 875 0.7× 804 1.3× 1.2k 2.5× 373 0.9× 265 4.8k

Countries citing papers authored by Roisín M. Connolly

Since Specialization
Citations

This map shows the geographic impact of Roisín M. Connolly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roisín M. Connolly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roisín M. Connolly more than expected).

Fields of papers citing papers by Roisín M. Connolly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roisín M. Connolly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roisín M. Connolly. The network helps show where Roisín M. Connolly may publish in the future.

Co-authorship network of co-authors of Roisín M. Connolly

This figure shows the co-authorship network connecting the top 25 collaborators of Roisín M. Connolly. A scholar is included among the top collaborators of Roisín M. Connolly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roisín M. Connolly. Roisín M. Connolly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noonan, Brendan, Josephine Hegarty, Mohamad M. Saab, et al.. (2025). Study protocol: LIAM Mc trial (Linking In with Advice and supports for Men impacted by Metastatic cancer). PLoS ONE. 20(4). e0313454–e0313454.
2.
Gatsonis, Constantine, Heather A. Jacene, Roisín M. Connolly, et al.. (2024). Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.. Journal of Clinical Oncology. 42(16_suppl). TPS614–TPS614.
3.
4.
Harvey, Harry, Derek G. Power, Dearbhaile Catherine Collins, et al.. (2023). A pilot project investigating the use of ONCOpatient®—An electronic patient-reported outcomes app for oncology patients. Digital Health. 9. 589829140–589829140. 5 indexed citations
5.
Nuzum, Daniel, Richard Bambury, Dearbhaile Catherine Collins, et al.. (2023). 1597P Improving in-hospital end-of-life care (EOLC) for oncology patients in a tertiary cancer centre. Annals of Oncology. 34. S887–S888.
6.
Connolly, Roisín M., Ciara C. O’Sullivan, Vamsidhar Velcheti, et al.. (2023). A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. The Oncologist. 28(5). 460–e298. 5 indexed citations
7.
Ballinger, Tarah J., Helga S. Marques, Richard L. Hoffman, et al.. (2023). Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112. Journal of the National Comprehensive Cancer Network. 21(9). 915–923.e1. 4 indexed citations
8.
Connolly, Roisín M., Fengmin Zhao, Kathy D. Miller, et al.. (2021). E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology. 39(28). 3171–3181. 76 indexed citations
9.
Walsh, Elaine M., John H. Fetting, Deborah K. Armstrong, et al.. (2021). Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Clinical Breast Cancer. 22(4). 319–325. 8 indexed citations
10.
Telli, Melinda L., Charles C. Chu, Sunil Badve, et al.. (2019). Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research. 26(11). 2704–2710. 23 indexed citations
11.
Litvak, Anya M., Stuart D. Russell, Hua‐Ling Tsai, et al.. (2018). Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer. Cancer. 124(9). 1904–1911. 61 indexed citations
12.
Goff, Laura W., Nilofer S. Azad, Stacey Stein, et al.. (2018). Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Investigational New Drugs. 37(2). 315–322. 13 indexed citations
13.
Beierl, Katie, Christopher D. Gocke, Daniel J. Zabransky, et al.. (2017). Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component. Clinical Cancer Research. 23(16). 4875–4884. 29 indexed citations
14.
Merino, Vanessa F., Nguyen Nguyen, Kideok Jin, et al.. (2016). Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. Cancer Research. 76(7). 2013–2024. 37 indexed citations
15.
Connolly, Roisín M., Fengmin Zhao, Kathy Ann Miller, et al.. (2015). E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.. Journal of Clinical Oncology. 9 indexed citations
16.
O’Sullivan, Ciara C. & Roisín M. Connolly. (2014). Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.. PubMed. 28(3). 186–94, 196. 14 indexed citations
17.
Magalhães, Maria Cristina Figueroa, Danijela Jelovac, Roisín M. Connolly, & Antonio C. Wolff. (2013). Treatment of HER2-positive breast cancer. The Breast. 23(2). 128–136. 191 indexed citations
18.
Connolly, Roisín M., et al.. (2013). Postmenopausal hormone receptor-positive advanced breast cancer.. PubMed. 27(6). 571–2, 574, 576 passim. 6 indexed citations
19.
Barron, Thomas I., Roisín M. Connolly, Linda Sharp, Kathleen Bennett, & Kala Visvanathan. (2011). Beta Blockers and Breast Cancer Mortality: A Population- Based Study. Journal of Clinical Oncology. 29(19). 2635–2644. 428 indexed citations
20.
Callejo, Sonia, et al.. (2003). Detection of Spiked Uveal Melanoma Cells in Peripheral Blood of Healthy Volunteers. Investigative Ophthalmology & Visual Science. 44(13). 1550–1550. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca L. Stone Breakdown of academic impact, for papers by Juan Lin Breakdown of academic impact, for papers by Michelle A.T. Hildebrandt Breakdown of academic impact, for papers by James Campbell Breakdown of academic impact, for papers by Giovanni Luca Gravina Breakdown of academic impact, for papers by Romano Demicheli Breakdown of academic impact, for papers by Nicola J. Mabjeesh Breakdown of academic impact, for papers by Antonio Silvani Breakdown of academic impact, for papers by Kurt Possinger Breakdown of academic impact, for papers by Alessandra Fabi
Rankless by CCL
2026